Generic Name: fosamprenavir

Pronunciation: lex-EE-vah

Abbreviation: FPV

Other Market Name: Telzir

Drug Class: Protease Inhibitors (PIs)

Pharmaceutical Company: ViiV Healthcare

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A


Drug Recommendation

Not part of a recommended or alternative treatment regimen for antiretroviral-naive people living with HIV, according to the U.S. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Visit http://aidsinfo.nih.gov/contentfiles/lvguidelines/aa_recommendations.pdf for the full DHHS guidelines.


General Info

Lexiva is an HIV medication. It is in a category of HIV medicines called protease inhibitors. Lexiva was approved by the U.S. Food and Drug Administration for use by people living with HIV in October 2003.

Lexiva must be combined with other HIV drugs and is often boosted by Norvir (ritonavir).


Dosage

Adult Dose: Two 700 mg tablets twice a day, or two 700 mg tablets plus one or two Norvir tablets once a day, or one 700 mg tablet plus one Norvir tablet  twice a day (recommended for individuals who have used other PIs in the past). Take with or without food.

Pediatric Dose: Age 4 weeks to 18 years: dosing based on body weight and should not exceed the adult daily dose.

Dosing Info: Take with or without food.


Side Effects

Side effects include rash, appetite loss, headaches, feeling crummy (malaise), diarrhea, nausea, and vomiting.

Severe, life-threatening rashes have been documented with Lexiva. People with a moderate rash and other allergic symptoms, and people with severe rashes should stop taking Lexiva.

Drug-induced hepatitis (liver injury) has been reported in people taking protease inhibitors, including Lexiva. This usually occurred in people who had extremely low CD4 cells, were taking multiple other medications and who were also infected with hepatitis B virus (HBV) or hepatitis C virus (HCV). Lab tests to monitor liver function is an important component of routine follow-up care and important for people using protease inhibitors.

Some people may experience increases in their lipid levels (triglycerides and cholesterol) or diabetes risk while being treated with protease inhibitors, including Lexiva.


Drug Interactions

Lexiva, particularly when combined with Norvir, can increase the levels of many other drugs in the body, potentially increasing the risk of serious side effects (some coadministered drugs can also decrease or increase lopinavir levels in the bloodstream). Dosage adjustments or substitutions may be necessary if you are prescribed certain medications from any of the following drug classes: antiarrhythmics, antibiotics, cancer chemotherapeutic drugs, anticoagulants, anticonvulsants, antidepressants, antifungals, anti-gout medications, antimalarial drugs, beta-blockers, calcium channel blockers, corticosteroids (oral and inhaled), endothelin receptor antagonists, hepatitis C medications, statins, hormonal contraceptives, immune-suppressants, inhaled beta agonists, narcotic medications (for pain and opioid dependence), neuroleptics/anti-seizure medications, erectile dysfunction drugs, and sedatives/hypnotics. Consult the Lexiva package insert for more details: http://www.viivhealthcare.com/gskprm/htdocs/documents/LEXIVA-PI-PIL.PDF


Other Info

Before taking this medication, tell your doctor if you have kidney disease or liver disease (including hepatitis B). In addition, tell your doctor if you are pregnant or planning to become pregnant, if you are breastfeeding, and all your medical conditions.

It is also very important that your health care provider and pharmacist know all prescription and over-the-counter medications and supplements you are taking at all times while using an HIV treatment regimen that contains Lexiva.


For More Info: http://www.viivhealthcare.com/gskprm/htdocs/documents/LEXIVA-PI-PIL.PDF

Co-Pay Program Info: https://www.poz.com/basics/hiv-basics/drug-assistance-programs

Patient Assistance Program Info: https://www.poz.com/basics/hiv-basics/drug-assistance-programs

Last Revised: July 15, 2016